Welcome to our dedicated page for Cybin SEC filings (Ticker: HELP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cybin Inc. filings document Helus Pharma's status as a foreign issuer reporting current events through Form 6-K materials and related exhibits. The filings include company news releases covering the HLP003 and HLP004 clinical programs, regulatory designations, clinical research collaborations, scientific advisory matters, and management changes.
The company's regulatory record also covers capital-structure disclosure, shareholder voting matters, governance matters, clinical or regulatory disclosures, operating and financial results, and risk-oriented cautionary statements associated with its clinical-stage pharmaceutical business.
Cybin Inc., operating commercially as Helus Pharma, reports that Nature Medicine has published results from a Phase 2a randomized, placebo-controlled trial of SPL026 in adults with moderate-to-severe major depressive disorder. The single 21.5 mg intravenous dose met the primary endpoint, delivering statistically and clinically meaningful reductions in Montgomery-Åsberg Depression Rating Scale scores at two weeks versus placebo (mean difference: -7.35). Antidepressant effects appeared within one week, were sustained to three months, and some participants improved for up to six months, with no treatment-related serious adverse events reported. Response rates at Week 2 were 35% for SPL026 versus 12% for placebo, and remission rates were 29% versus 12%. Although intravenous SPL026 is not being advanced, the data support Helus’s short-acting serotonergic agonist approach and inform its HLP004 program, with Phase 2 topline data in generalized anxiety disorder expected in Q1 2026.
Cybin Inc., operating commercially as Helus Pharma, reports that Nature Medicine has published results from a Phase 2a randomized, placebo-controlled trial of SPL026 in adults with moderate-to-severe major depressive disorder. The single 21.5 mg intravenous dose met the primary endpoint, delivering statistically and clinically meaningful reductions in Montgomery-Åsberg Depression Rating Scale scores at two weeks versus placebo (mean difference: -7.35). Antidepressant effects appeared within one week, were sustained to three months, and some participants improved for up to six months, with no treatment-related serious adverse events reported. Response rates at Week 2 were 35% for SPL026 versus 12% for placebo, and remission rates were 29% versus 12%. Although intravenous SPL026 is not being advanced, the data support Helus’s short-acting serotonergic agonist approach and inform its HLP004 program, with Phase 2 topline data in generalized anxiety disorder expected in Q1 2026.
Tang Capital Management and related entities have exited their stake in Cybin Inc. In Amendment No. 3 to a Schedule 13G, Tang Capital Management, Kevin Tang, and affiliated partnerships and corporations report beneficial ownership of 0 shares of Cybin common stock, or 0% of the class, as of December 31, 2025.
The filing confirms they no longer have sole or shared voting or dispositive power over any Cybin shares and state that the securities were not acquired or held to change or influence control of the company.
Tang Capital Management and related entities have exited their stake in Cybin Inc. In Amendment No. 3 to a Schedule 13G, Tang Capital Management, Kevin Tang, and affiliated partnerships and corporations report beneficial ownership of 0 shares of Cybin common stock, or 0% of the class, as of December 31, 2025.
The filing confirms they no longer have sole or shared voting or dispositive power over any Cybin shares and state that the securities were not acquired or held to change or influence control of the company.
Deep Track Capital and affiliated entities report owning 2,391,505 Cybin Inc. common shares, representing 4.74% of the class as of December 31, 2025. The position includes 537,250 warrants exercisable into common stock, subject to a 9.99% maximum beneficial ownership limitation.
The ownership calculation uses 50,431,381 shares, based on 49,894,131 common shares outstanding as of December 19, 2025 plus the warrants counted up to the stated cap. The filers certify the holdings are not for the purpose of changing or influencing control of Cybin.
Deep Track Capital and affiliated entities report owning 2,391,505 Cybin Inc. common shares, representing 4.74% of the class as of December 31, 2025. The position includes 537,250 warrants exercisable into common stock, subject to a 9.99% maximum beneficial ownership limitation.
The ownership calculation uses 50,431,381 shares, based on 49,894,131 common shares outstanding as of December 19, 2025 plus the warrants counted up to the stated cap. The filers certify the holdings are not for the purpose of changing or influencing control of Cybin.
Helus Pharma, formerly Cybin Inc., reported a larger loss but a much stronger balance sheet for the three and nine months ended December 31, 2025. The company, a clinical-stage pharmaceutical developer of novel serotonergic agonists, posted a nine‑month net loss of $101,003 compared with $60,300 a year earlier, driven mainly by higher research spending of $57,702 and general and administrative costs of $31,419.
Despite the wider loss, liquidity improved significantly. Cash increased to $195,128 from $93,922 as of March 31, 2025, supported by net financing inflows of $198,408, including a registered direct offering of 22,277,750 common shares and 4,605,500 pre‑funded warrants with gross proceeds of about $175,010, and an earlier at‑the‑market program raising $10,465. Total assets rose to $290,112 and shareholders’ equity to $273,934, while the accumulated deficit reached $342,540.
The company issued and then fully extinguished $50,000 of unsecured convertible debentures during the period, recognizing a fair value loss of $5,500 before repaying the remaining principal and fees. It also expanded equity‑based incentives, with 4,169,617 stock options, 12,205,335 warrants, 4,605,500 pre‑funded warrants and 4,164,440 restricted share units outstanding at December 31, 2025. Helus Pharma subsequently moved its U.S. listing to Nasdaq under the symbol “HELP” and notes clinical and commercial commitments, including up to $109,950 for contracted studies and milestone obligations of up to $9,500 under a license agreement, alongside ongoing development of its HLP003, HLP004 and HLP005 programs.
Helus Pharma, formerly Cybin Inc., reported a larger loss but a much stronger balance sheet for the three and nine months ended December 31, 2025. The company, a clinical-stage pharmaceutical developer of novel serotonergic agonists, posted a nine‑month net loss of $101,003 compared with $60,300 a year earlier, driven mainly by higher research spending of $57,702 and general and administrative costs of $31,419.
Despite the wider loss, liquidity improved significantly. Cash increased to $195,128 from $93,922 as of March 31, 2025, supported by net financing inflows of $198,408, including a registered direct offering of 22,277,750 common shares and 4,605,500 pre‑funded warrants with gross proceeds of about $175,010, and an earlier at‑the‑market program raising $10,465. Total assets rose to $290,112 and shareholders’ equity to $273,934, while the accumulated deficit reached $342,540.
The company issued and then fully extinguished $50,000 of unsecured convertible debentures during the period, recognizing a fair value loss of $5,500 before repaying the remaining principal and fees. It also expanded equity‑based incentives, with 4,169,617 stock options, 12,205,335 warrants, 4,605,500 pre‑funded warrants and 4,164,440 restricted share units outstanding at December 31, 2025. Helus Pharma subsequently moved its U.S. listing to Nasdaq under the symbol “HELP” and notes clinical and commercial commitments, including up to $109,950 for contracted studies and milestone obligations of up to $9,500 under a license agreement, alongside ongoing development of its HLP003, HLP004 and HLP005 programs.
Cybin Inc.’s commercial operating unit Helus Pharma has appointed industry veteran Michael Cola as Chief Executive Officer, effective immediately. He brings more than 30 years of experience in neuroscience, rare disease and specialty pharmaceuticals, including leading Shire’s Specialty Pharmaceutical business and senior roles at Astra-Merck and AstraZeneca.
Helus is advancing a pipeline of novel serotonergic agonists for serious mental health disorders, with Phase 2 data for HLP004 expected in the first quarter of 2026 and Phase 3 topline data for HLP003 expected in the fourth quarter of 2026. The company has filed more than 350 patent applications globally and has been granted over 100 patents as it moves from early clinical development toward later-stage execution, global regulatory engagement and long-term commercial planning.
Cybin Inc.’s commercial operating unit Helus Pharma has appointed industry veteran Michael Cola as Chief Executive Officer, effective immediately. He brings more than 30 years of experience in neuroscience, rare disease and specialty pharmaceuticals, including leading Shire’s Specialty Pharmaceutical business and senior roles at Astra-Merck and AstraZeneca.
Helus is advancing a pipeline of novel serotonergic agonists for serious mental health disorders, with Phase 2 data for HLP004 expected in the first quarter of 2026 and Phase 3 topline data for HLP003 expected in the fourth quarter of 2026. The company has filed more than 350 patent applications globally and has been granted over 100 patents as it moves from early clinical development toward later-stage execution, global regulatory engagement and long-term commercial planning.